207 related articles for article (PubMed ID: 29748589)
1. Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy.
Huang HS; Su HY; Li PH; Chiang PH; Huang CH; Chen CH; Hsieh MC
Sci Rep; 2018 May; 8(1):7485. PubMed ID: 29748589
[TBL] [Abstract][Full Text] [Related]
2. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
Moschini M; Shariat SF; Rouprêt M; De Santis M; Bellmunt J; Sternberg CN; Tombal B; Collette L
J Urol; 2018 May; 199(5):1149-1157. PubMed ID: 29158104
[TBL] [Abstract][Full Text] [Related]
3. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
[No Abstract] [Full Text] [Related]
4. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
Sonpavde GP; Mariani L; Lo Vullo S; Raggi D; Giannatempo P; Bamias A; Crabb SJ; Bellmunt J; Yu EY; Niegisch G; Vaishampayan UN; Theodore C; Berthold DR; Srinivas S; Sridhar SS; Plimack ER; Rosenberg JE; Powles T; Galsky MD; Necchi A
J Urol; 2018 Dec; 200(6):1207-1214. PubMed ID: 30012366
[TBL] [Abstract][Full Text] [Related]
5. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
[TBL] [Abstract][Full Text] [Related]
6. Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data.
Ricci AD; Rizzo A; Mollica V; Schiavina R; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
Anticancer Drugs; 2022 Jan; 33(1):e61-e68. PubMed ID: 34387596
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
[TBL] [Abstract][Full Text] [Related]
8. The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer.
Liu K; Zhao K; Wang L; Sun E
Pathol Res Pract; 2018 Aug; 214(8):1074-1080. PubMed ID: 29803657
[TBL] [Abstract][Full Text] [Related]
9. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
[TBL] [Abstract][Full Text] [Related]
10. Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Sonpavde G; Manitz J; Gao C; Tayama D; Kaiser C; Hennessy D; Makari D; Gupta A; Abdullah SE; Niegisch G; Rosenberg JE; Bajorin DF; Grivas P; Apolo AB; Dreicer R; Hahn NM; Galsky MD; Necchi A; Srinivas S; Powles T; Choueiri TK; Pond GR
J Urol; 2020 Dec; 204(6):1173-1179. PubMed ID: 32552295
[TBL] [Abstract][Full Text] [Related]
11. Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy.
Ishiyama Y; Kondo T; Nemoto Y; Kobari Y; Ishihara H; Tachibana H; Yoshida K; Hashimoto Y; Takagi T; Iizuka J; Tanabe K
Anticancer Res; 2021 Mar; 41(3):1607-1614. PubMed ID: 33788756
[TBL] [Abstract][Full Text] [Related]
12. Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery.
Urakami S; Yuasa T; Yamamoto S; Sakura M; Tanaka H; Hayashi T; Uehara S; Inoue Y; Fujii Y; Masuda H; Fukui I; Yonese J
Int J Clin Oncol; 2015 Dec; 20(6):1171-8. PubMed ID: 25953680
[TBL] [Abstract][Full Text] [Related]
13. Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy.
Hsieh MC; Su YL; Chiang PH; Rau KM; Chen YY; Huang CH
Int J Urol; 2016 May; 23(5):385-9. PubMed ID: 26992082
[TBL] [Abstract][Full Text] [Related]
14. Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.
Mullane SA; Werner L; Guancial EA; Lis RT; Stack EC; Loda M; Kantoff PW; Choueiri TK; Rosenberg J; Bellmunt J
Clin Genitourin Cancer; 2016 Aug; 14(4):352-9. PubMed ID: 26778300
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.
Auvray M; Elaidi R; Ozguroglu M; Guven S; Gauthier H; Culine S; Caty A; Dujardin C; Auclin E; Thibaut C; Combe P; Tartour E; Oudard S
Clin Genitourin Cancer; 2017 Jun; 15(3):e469-e476. PubMed ID: 27964892
[TBL] [Abstract][Full Text] [Related]
16. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
Sonpavde G; Pond GR; Di Lorenzo G; Buonerba C; Rozzi A; Lanzetta G; Necchi A; Giannatempo P; Raggi D; Matsumoto K; Choueiri TK; Mullane S; Niegisch G; Albers P; Lee JL; Kitamura H; Kume H; Bellmunt J
Clin Genitourin Cancer; 2016 Dec; 14(6):494-498. PubMed ID: 27262369
[TBL] [Abstract][Full Text] [Related]
17. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.
Taguchi S; Nakagawa T; Matsumoto A; Nagase Y; Kawai T; Tanaka Y; Yoshida K; Yamamoto S; Enomoto Y; Nose Y; Sato T; Ishikawa A; Uemura Y; Fujimura T; Fukuhara H; Kume H; Homma Y
Int J Urol; 2015 Jul; 22(7):638-43. PubMed ID: 25903328
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma.
Maiorano BA; Schinzari G; Carbone C; Piro G; Rossi E; Di Maio M; Di Giacomo A; Maiello E
Front Immunol; 2024; 15():1401214. PubMed ID: 38799450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
